Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. multicenter phase III clinical trials. Efficacy of early imaging

Journal of Magnetic Resonance Imaging

Volumn 12, Issue 5, 2000, Pages 689-701

  Federle, Michael ^a   Chezmar, Judith ^b   Rubin, Daniel L ^c   Weinreb, Jeffrey ^d   Freeny, Patrick ^e   Schmiedl, Udo P ^e   Brown, Jeffrey J ^f   Borrello, Joseph A ^g   Lee, Joseph K T ^h   Semelka, Richard C ^h   Mattrey, Robert ⁱ   Dachman, Abraham H ^j   Saini, Sanjay ^k   Harms, Steven E ^l   Mitchell, Donald G ^a   Anderson, Mark W ^m   Halford III, Hollis H ⁿ   Bennett, William F ^o   Young, Stuart W ^p   Rifkin, Matthew ^q   Gay, Spencer B ^r   Ballerini, Rocco ^s   Sherwin, Paul F ^t   Robison, Ronald O ^s   more..

^a PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

^c Good Samaritan Hospital San Jose   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Kalamazoo Radiology   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ UCSD MEDICAL CENTER   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l Veterans Administration Memorial Hospital   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ Methodist North Hospital   (United States)

^o THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^p SUNY at Stony Brook ^*

^q STONY BROOK UNIVERSITY   (United States)

^r UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^s Amersham Biosciences   (United States)

^t Amersham Laboratories   (United Kingdom)

more..

Author keywords

Cirrhosis; Contrast media; Efficacy; Liver neoplasms; Mangafodipir trisodium; Manganese; MnDPDP; MRI; Teslascan

Indexed keywords

CONTRAST MEDIUM; MANGAFODIPIR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CIRRHOSIS; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; EDETIC ACID; FEMALE; HUMANS; IMAGE ENHANCEMENT; INJECTIONS, INTRAVENOUS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PYRIDOXAL PHOSPHATE; SENSITIVITY AND SPECIFICITY;

EID: 0033754826     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/1522-2586(200011)12:5<689::AID-JMRI5>3.0.CO;2-Z     Document Type: Article

References (68)

1. Imaging hepatic metastases from colorectal carcinoma: Identification of candidates for partial hepatectomy
2. Detection of focal hepatic masses: Prospective evaluation with CT, delayed CT, CT during arterial portography, and MR imaging
3. Dynamic contrast-enhanced CT of the liver: Comparison of contrast medium injection rates and uniphasic and biphasic injection protocols
4. Contrast-enhanced MR imaging of the liver
5. Preclinical evaluation of Mn-DPDP: New paramagnetic hepatobiliary contrast agent for MR imaging
6. Hepatobiliary MR imaging: First human experience with MnDPDP
7. Hepatocellular tumors: Characterization with Mn-DPDP-enhanced MR imaging
8. Contrast-enhanced magnetic resonance imaging of the liver with Mn-DPDP for known or suspected focal hepatic disease
9. Hepatic MR imaging with Mn-DPDP: Safety, image quality, and sensitivity
10. Comparison of contrast enhanced CT and Mn-DPDP enhanced MRI for detection of focal hepatic lesions: Initial findings
11. Focal liver lesions: MR imaging with MnDPDP. Initial clinical results in 40 patients
12. Mn-DPDP enhancement patterns of hepatocellular lesions on MR images
13. Mn-DPDP-enhanced MR imaging of malignant liver lesions: Efficacy and safety in 20 patients
14. Manganese-DPDP as a hepatobiliary contrast agent in the magnetic resonance imaging of liver tumors. Results of clinical phase II trials in Germany including 141 patients
15. Manganese DPDP as a contrast medium for MRI of focal liver lesions: Patient acceptability and image quality in 20 patients
16. The clinical value of Mn-DPDP: A new paramagnetic hepatobiliary contrast medium for magnetic resonance tomography of the liver
17. Malignant liver tumors in hepatobiliary MR imaging with Mn-DPDP
18. Mn-DPDP: Safety profile after phase II clinical trials in 140 patients
19. Value of Mn-DPDP-enhanced MR imaging of liver tumors in 141 patients: Results of phase II trials in Germany
20. The efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. multicenter phase III clinical trials
21. The safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. multicenter phase III clinical trials
22. Overview of MnDPDP as a pancreas-specific contrast agent for MR imaging
23. Pancreatic contrast enhancement with Mn-bis pyridoxal ethylene diamine diacetic acid and the influence of a hormonal stimulation of the pancreas in pigs
24. MR imaging assessment of experimental hepatic dysfunction with MnDPDP
25. Comparative assessment of gadoxetate disodium, manganese dipyridoxal diphosphate, and superparamagnetic iron oxide for enhancement of the liver in dogs
26. Enhanced tumor detection in the presence of fatty liver disease: Cell-specific contrast agents
27. MRI contrast media for the liver. Efficacy in conditions of acute biliary obstruction
28. CT and MR imaging of the liver using liver-specific contrast media. A comparative study in a tumour model
29. Mn-DPDP enhanced MRI in experimental bile duct obstruction
30. Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: A correlation study of MR imaging, microangiography, and histology
31. Manganese dipyridoxal diphosphate. Effect of dose, time, and pulse sequence on hepatic enhancement in rats
32. Magnetic resonance imaging after arterial portography with manganese dipyridoxal diphosphate
33. The uptake of manganese dipyridoxal-diphosphate by chemically induced hepatocellular carcinoma in rats. A correlation between contrast-media-enhanced magnetic resonance imaging, tumor differentiation, and vascularization
34. Comparison of manganese biodistribution and MR contrast enhancement in rats after intravenous injection of MnDPDP and MnC12
35. Effect of manganese dipyridoxal diphosphate on liver magnetic resonance imaging and serum bilirubin in rats with removable biliary obstruction
36. Magnetic resonance imaging of acute myocardial ischemia using a manganese chelate, Mn-DPDP
37. Formulation of radiographically detectable gastrointestinal contrast agents for magnetic resonance imaging: Effects of a barium sulfate additive on MR contrast agent effectiveness
38. Manganese dipyridoxal diphosphate-enhanced magnetic resonance imaging in the evaluation of hepatocyte function
39. NMR relaxation studies with MnDPDP
40. Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis
41. MnDPDP enhancement in rabbit liver after intravenous bolus injection and slow infusion
42. Detection of hepatic malignancies using MnDPDP (manganese dipyridoxal diphosphate) hepatobiliary MRI contrast agent
43. MRI measurement of hepatocyte toxicity using the new MRI contrast agent manganese dipyridoxal diphosphate, a manganese/pyridoxal 5-phosphate chelate
44. Metabolism and pharmacokinetics of MnDPDP in man
45. MR imaging properties and pharmacokinetics of MnDPDP in healthy volunteers
46. Pharmacokinetics and biotransformation of the MRI liver contrast agent mangafodipir trisodium injection in normal human male volunteers
47. Manganese (II) N,N'-dipyridoxalethyl-enediamine-N,N'-diacetate 5,5'-bis(phosphate): Clinical experience with a new contrast agent
48. Mangafodipir trisodium injection (Mn-DPDP): A contrast agent for abdominal MR imaging
49. Manganese-DPDP-enhanced MRI of liver metastases
50. Manganese dipyridoxal diphosphate as a new contrast medium in the MRT of benign and malignant pancreatic tumors: Initial clinical findings
51. Mn-DPDP in MR imaging of pancreatic adenocarcinoma: Initial clinical experience
52. MnDPDP in detection of pancreatic lesions with MR imaging. Results of a phase II trial
53. Mn-DPDP enhanced imaging of the kidneys. First results of signal intensity changes and corticomedullary differentiation after low-dosage infusion
54. Pancreatic enhancement after low-dose infusion of Mn-DPDP
55. Gegenwartiger stand der klinischen entwicklung von MR-kontrastmitteln
56. Mn-DPDP in the detection of hepatic tumors: Results of clinical multicenter trials including 140 patients
57. Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicenter study
58. MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies
59. MnDPDP for MR imaging of the liver. Results from the European phase III studies
60. Tumoural portal vein thrombosis. Enhancement with MnDPDP
61. MnDPD-enhanced MR imaging of the liver. Correlation with surgical findings
62. Tolerability and utility of mangafodipir trisodium injection (MnDPDP) at the dose of 5 μmol/kg body weight in detecting focal liver tumors: Results of a phase III trial using an infusion technique
63. MnDPDP as a negative hepatic contrast agent: Evaluation of STIR imaging compared with T1-weighted SE and GE techniques
64. Inflammatory pseudotumor of the liver: MRI with mangafodipir trisodium
65. Testing marginal homogeneity or ordinal categorical variables
66. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP)
67. Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP)